GlassScriptPhysician profile
Garth George
NPI 1760453286
$14,869.28
in general payments reported to CMS, 2019-2025
39 companies · $2,637 in 2025
The $2,637 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,564 · 2020: $677 · 2021: $1,445 · 2022: $1,632 · 2023: $2,125 · 2024: $2,789 · 2025: $2,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,474 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,474.21 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,821.52 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $2,683.13 | 2019-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,596.67 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $1,380.80 | 2019-2025 | Livdelzi |
| Janssen Biotech, INC. | $781.14 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $547.51 | 2019-2025 | |
| Celgene Corporation | $535.18 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $456.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $330.28 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $301.75 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Nestle Healthcare Nutrition INC. | $243.80 | 2021-2023 | |
| Qol Medical, LLC | $238.73 | 2023-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $223.21 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $199.97 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $182.91 | 2024-2025 | Zenpep |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $172.95 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $157.79 | 2019-2025 | Linzess |
| Ferring Pharmaceuticals INC. | $147.66 | 2020-2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $127.59 | 2022-2024 | Dupixent |
| Daiichi Sankyo INC. | $91.22 | 2020-2022 | |
| Exact Sciences Corporation | $79.34 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Evoke Pharma, INC. | $74.52 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $66.95 | 2019-2020 | |
| Braintree Laboratories, INC. | $56.88 | 2019-2022 | |
| Organon LLC | $50.08 | 2023-2024 | Hadlima |
| Intra-Sana Laboratories | $49.28 | 2022 | |
| Lilly USA, LLC | $33.37 | 2025 | Omvoh |
| Allergan, INC. | $31.30 | 2019-2020 | |
| Redhill Biopharma INC. | $28.91 | 2021 | |
| Medtronic, INC. | $28.58 | 2021-2023 | Gi Genius |
| Novo Nordisk INC | $24.51 | 2025 | Wegovy |
| Smith+Nephew, INC. | $20.90 | 2022 | |
| Ucb, INC. | $16.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.17 | 2023 | Cyltezo |
| Applied Medical Technology INC | $15.96 | 2023 | Amt Balloon G-Tube, Amt Capsule Monarch G-Tube, Traditional G-Jet |
| Kci USA, INC. | $15.47 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.31 | 2023 | Seglentis |
| Olympus America INC. | $13.96 | 2023 | Endoclot Phs |
| Davol INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garth George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.